Stock 4554 FUJI PHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Fuji Pharma Co., Ltd.

Equities

4554

JP3816200004

Delayed Japan Exchange
Other stock markets
 11:30:00 25/06/2024 am IST 		5-day change 1st Jan Change
1,437 JPY -0.48% Intraday chart for Fuji Pharma Co., Ltd. -1.78% -17.37%
2023 Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump MT
2023 Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company appears to be poorly valued given its net asset value.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
FUJI PHARMA CO., LTD. Stock Fuji Pharma Co., Ltd.
-17.37% 22Cr -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.19% 80TCr
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+47.26% 63TCr
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.09% 36TCr
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.92% 34TCr
B-
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.40% 25TCr
B+
ROCHE HOLDING AG Stock Roche Holding AG
+3.64% 23TCr
A+
NOVARTIS AG Stock Novartis AG
+12.98% 22TCr
B-
AMGEN INC. Stock Amgen Inc.
+10.86% 17TCr
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.78% 16TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 4554 Stock
  4. Ratings Fuji Pharma Co., Ltd.